Company will be seeking alignment to begin rolling BLA submission NEW YORK--(BUSINESS WIRE)-- OS Therapies (OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug ...
We credit FDA with taking decisive action to help advance Accelerated Approval discussions regarding OST-HER2 for pediatric cancer patients with osteosarcoma.” — Paul Romness, MPH, Chairman & CEO of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results